Cosmos Health Inc. (COSM)
| Market Cap | 33.85M +9.9% |
| Revenue (ttm) | 73.73M +33.8% |
| Net Income | -24.39M |
| EPS | -0.57 |
| Shares Out | 100.63M |
| PE Ratio | n/a |
| Forward PE | 33.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,722,744 |
| Open | 0.3730 |
| Previous Close | 0.3829 |
| Day's Range | 0.3250 - 0.3790 |
| 52-Week Range | 0.1616 - 1.2550 |
| Beta | 4.21 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 16, 2026 |
About COSM
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), N... [Read more]
Financial Performance
In 2025, Cosmos Health's revenue was $65.27 million, an increase of 19.93% compared to the previous year's $54.43 million. Losses were -$19.14 million, -14.45% less than in 2024.
Financial StatementsNews
Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
● 6,287 active U.S. subscriptions as of October 14, 2026, the vast majority added since mid-September as the Company accelerates investment in its U.S. platform ● 60.5% of U.S. online checkout orders ...
Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
Record day: U.S. direct-to-consumer sales exceeded $92,000 on October 11, 2026, the highest single day to date $902,000 in 30 days: approximately $30,000 in average daily sales over the trailing 30-da...
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
Record nine-month revenue of approximately $54.3 million - up 19%, or $8.7 million, from $45.6 million in the same period of 2025 Nine-month 2026 revenue nearly matches the whole of 2024 - when full-y...
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded generics Proprie...
Cosmos Health’s CosmoFarm reaches annualized revenue above $60M
Cosmos Health (COSM) provided an update on its wholly owned pharmaceutical distribution subsidiary, CosmoFarm, which delivered record revenue of over $15M in the second quarter of 2026, representing a...
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm Revenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal...
Cosmos’ contract manufacturing division surpasses $20M in implied revenue
Cosmos Health (COSM) announced that the contract manufacturing pipeline of its wholly owned subsidiary, Cana Laboratories, has surpassed $20M in implied revenue over the life of the underlying agreeme...
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreemen...
Cosmos Health secures five-year contract manufacturing agreement
Cosmos Health (COSM) announced that its wholly owned subsidiary, Cana Laboratories, has secured new five-year contract manufacturing agreements with Target Pharma totaling approximately 5.2M units. Th...
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today Secured orders for 1.04 mill...
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock Positions Cosmos Hea...
Cosmos Health secures five-year contract manufacturing agreement
Cosmos Health’s (COSM) Cana Laboratories secured a new five-year contract manufacturing agreement with Viofar covering approximately 2.5M units of ROSARTIA. The agreement represents approximately 500,...
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories Expands Cosmos Health's manufacturing presenc...
Cosmos Health launches C-ScrubVet in the UK
Cosmos Health (COSM) has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet. C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial…
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
First orders received for the Company's veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet Formulated for dogs, cats, horses, companion and large animals, and suppli...
Cosmos Health: A Company Transformed — 2026 Year-to-Date
A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026 Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1...
Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions
$8 million senior secured ATW convertible note satisfied, together with all accrued interest, twelve months ahead of its August 2027 maturity and eliminating any further dilution Simplified capital st...
Cosmos Health sees over $6M in incremental annual U.S. revenue from Oliv18
Cosmos Health (COSM) announced it is projecting Oliv18 to generate over $6M in incremental annual U.S. revenue within the next 12 to 18 months, representing approximately $4.3M in gross profit…
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories.
Cosmos Health announces distribution agreement with Innova Healthcare
Cosmos Health (COSM) announced an exclusive distribution agreement with Innova Healthcare covering the Company’s proprietary Sky Premium Life range of food supplements across the Kingdom of Saudi Arab...
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term
Cosmos Health Enters Saudi Arabia. Signs Exclusive Distribution Agreement With Innova Healthcare; Secures Purchase Order of 126,000 Sky Premium Life Units.
Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 million Continued pro...
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
Digital subscription platform brings together the Company's proprietary consumer health products across consumer (B2C) and corporate (B2B) channels Customers can begin through one of three paths: a fr...
Cosmos Health expands Sky Premium Life distribution pact with Pharma Cell
Cosmos Health (COSM) announced an expansion of its partnership with Pharma Cell for the distribution of its Sky Premium Life brand in Albania. Building on the partnership the companies launched…
Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units
Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are dist...